Cargando…
Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
Background: Insulin resistance plays a relevant role in the onset of non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and fibrosis. Irisin is an exercise-induced myokine involved in the regulation of energy homeostasis and glucose metabolism. Addi...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837035/ https://www.ncbi.nlm.nih.gov/pubmed/35160087 http://dx.doi.org/10.3390/jcm11030635 |
_version_ | 1784649825394884608 |
---|---|
author | Armandi, Angelo Rosso, Chiara Nicolosi, Aurora Caviglia, Gian Paolo Abate, Maria Lorena Olivero, Antonella D’Amato, Daphne Vernero, Marta Gaggini, Melania Saracco, Giorgio Maria Ribaldone, Davide Giuseppe Leeming, Diana Julie Gastaldelli, Amalia Bugianesi, Elisabetta |
author_facet | Armandi, Angelo Rosso, Chiara Nicolosi, Aurora Caviglia, Gian Paolo Abate, Maria Lorena Olivero, Antonella D’Amato, Daphne Vernero, Marta Gaggini, Melania Saracco, Giorgio Maria Ribaldone, Davide Giuseppe Leeming, Diana Julie Gastaldelli, Amalia Bugianesi, Elisabetta |
author_sort | Armandi, Angelo |
collection | PubMed |
description | Background: Insulin resistance plays a relevant role in the onset of non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and fibrosis. Irisin is an exercise-induced myokine involved in the regulation of energy homeostasis and glucose metabolism. Additionally, pre-clinical models have shown a potential role of irisin in the pathogenesis of NAFLD. The aim of this study is to explore the association between irisin, histological features and biomarkers of liver fibrogenesis in non-diabetic, non-obese, biopsy-proven NAFLD individuals. Methods: Forty-one patients with histological evidence of NAFLD were included. Circulating irisin and direct markers of fibrogenesis N-terminal type III collagen propeptide (PRO-C3) and type VI collagen cleavage product (PRO-C6) were measured by ELISA. Results: Median age of the cohort was 45 years (41–51) and 80.4% were male. Significant fibrosis (stage ≥ 2) was present in 36.6% of cases. Circulating irisin, PRO-C3 and PRO-C6 levels were significantly higher in subjects with fibrosis stage ≥ 2 when compared to those with fibrosis stage < 2 (5.96 ng/mL (95% CI = 4.42–9.19) vs. 2.42 ng/mL (95% CI = 1.73–5.95), p = 0.033; 9.5 ng/mL (95% CI = 7.7–13.6) vs. 6.2 ng/mL (95% CI = 4.9–8.9), p = 0.016; 6.6 ng/mL (95% CI = 5.6–7.9) vs. 5.1 ng/mL (95% CI = 4.2–5.4), p = 0.013, respectively). Irisin levels were similarly distributed between the features of NASH. Circulating irisin positively correlated with both PRO-C3 and PRO-C6 levels (r = 0.47, p = 0.008 and r = 0.46, p = 0.002). Conclusions: Increased circulating irisin levels may identify a more aggressive phenotype of liver disease with increased fibrogenesis and more severe liver damage. |
format | Online Article Text |
id | pubmed-8837035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88370352022-02-12 Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease Armandi, Angelo Rosso, Chiara Nicolosi, Aurora Caviglia, Gian Paolo Abate, Maria Lorena Olivero, Antonella D’Amato, Daphne Vernero, Marta Gaggini, Melania Saracco, Giorgio Maria Ribaldone, Davide Giuseppe Leeming, Diana Julie Gastaldelli, Amalia Bugianesi, Elisabetta J Clin Med Article Background: Insulin resistance plays a relevant role in the onset of non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and fibrosis. Irisin is an exercise-induced myokine involved in the regulation of energy homeostasis and glucose metabolism. Additionally, pre-clinical models have shown a potential role of irisin in the pathogenesis of NAFLD. The aim of this study is to explore the association between irisin, histological features and biomarkers of liver fibrogenesis in non-diabetic, non-obese, biopsy-proven NAFLD individuals. Methods: Forty-one patients with histological evidence of NAFLD were included. Circulating irisin and direct markers of fibrogenesis N-terminal type III collagen propeptide (PRO-C3) and type VI collagen cleavage product (PRO-C6) were measured by ELISA. Results: Median age of the cohort was 45 years (41–51) and 80.4% were male. Significant fibrosis (stage ≥ 2) was present in 36.6% of cases. Circulating irisin, PRO-C3 and PRO-C6 levels were significantly higher in subjects with fibrosis stage ≥ 2 when compared to those with fibrosis stage < 2 (5.96 ng/mL (95% CI = 4.42–9.19) vs. 2.42 ng/mL (95% CI = 1.73–5.95), p = 0.033; 9.5 ng/mL (95% CI = 7.7–13.6) vs. 6.2 ng/mL (95% CI = 4.9–8.9), p = 0.016; 6.6 ng/mL (95% CI = 5.6–7.9) vs. 5.1 ng/mL (95% CI = 4.2–5.4), p = 0.013, respectively). Irisin levels were similarly distributed between the features of NASH. Circulating irisin positively correlated with both PRO-C3 and PRO-C6 levels (r = 0.47, p = 0.008 and r = 0.46, p = 0.002). Conclusions: Increased circulating irisin levels may identify a more aggressive phenotype of liver disease with increased fibrogenesis and more severe liver damage. MDPI 2022-01-27 /pmc/articles/PMC8837035/ /pubmed/35160087 http://dx.doi.org/10.3390/jcm11030635 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Armandi, Angelo Rosso, Chiara Nicolosi, Aurora Caviglia, Gian Paolo Abate, Maria Lorena Olivero, Antonella D’Amato, Daphne Vernero, Marta Gaggini, Melania Saracco, Giorgio Maria Ribaldone, Davide Giuseppe Leeming, Diana Julie Gastaldelli, Amalia Bugianesi, Elisabetta Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease |
title | Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease |
title_full | Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease |
title_fullStr | Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease |
title_full_unstemmed | Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease |
title_short | Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease |
title_sort | crosstalk between irisin levels, liver fibrogenesis and liver damage in non-obese, non-diabetic individuals with non-alcoholic fatty liver disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837035/ https://www.ncbi.nlm.nih.gov/pubmed/35160087 http://dx.doi.org/10.3390/jcm11030635 |
work_keys_str_mv | AT armandiangelo crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT rossochiara crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT nicolosiaurora crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT cavigliagianpaolo crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT abatemarialorena crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT oliveroantonella crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT damatodaphne crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT verneromarta crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT gagginimelania crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT saraccogiorgiomaria crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT ribaldonedavidegiuseppe crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT leemingdianajulie crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT gastaldelliamalia crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease AT bugianesielisabetta crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease |